arterolane and piperaquine

P01BX02

Forms & Strengths

Fixed-dose combination tablet: arterolane maleate 150 mg / piperaquine tetraphosphate 750 mg

Adult Dosing

Uncomplicated Plasmodium falciparum malaria: 1 tablet once daily for 3 consecutive days (total 3 doses)

Pediatric Dosing

Safety and efficacy not established in children weighing less than a specified threshold or below certain age limits per regional guidelines; typically dosed by weight band per national malaria treatment protocols

Indications

Treatment of acute uncomplicated Plasmodium falciparum malaria in adults and children

Mechanism of Action

Arterolane is a synthetic peroxide (ozonide) with a fast-acting schizonticidal effect via generation of free radicals mediated by intraparasitic iron
Piperaquine is a bisquinoline antimalarial that inhibits heme polymerization within the parasite food vacuole, providing a longer elimination half-life for residual parasite clearance

Contraindications

Known hypersensitivity to arterolane, piperaquine, or any component of the formulation
Severe malaria
History of QT prolongation or known congenital long QT syndrome
History of symptomatic arrhythmias or clinically significant bradycardia
Concomitant administration with drugs that prolong the QT interval

Adverse Reactions

Drug Interactions

Avoid concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) which may decrease arterolane or piperaquine concentrations
Avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) which may increase drug exposure
Avoid concomitant administration of medications known to prolong the QT interval (e.g., antiarrhythmics, macrolide antibiotics, antipsychotics) due to additive risk of fatal cardiac arrhythmias

Curated Content: Needs Vetting Before Put to Clinical Use